Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocaratuzumab

Drug Profile

Ocaratuzumab

Alternative Names: AME-133; AME-133v; LY 2469298

Latest Information Update: 05 Feb 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Applied Molecular Evolution
  • Developer Applied Molecular Evolution; MENTRIK Biotech
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Follicular lymphoma; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 04 Feb 2016 No development reported - Phase-I for Rheumatoid arthritis in USA (IV)
  • 04 Feb 2016 No development reported - Phase-II for Follicular lymphoma in Japan (IV)
  • 04 Feb 2016 No development reported - Phase-II for Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top